CRISPR Therapeutics AG $CRSP Shares Acquired by UBS Group AG

UBS Group AG increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 7.7% during the 4th quarter, Holdings Channel reports. The fund owned 2,524,144 shares of the company’s stock after purchasing an additional 180,580 shares during the quarter. UBS Group AG’s holdings in CRISPR Therapeutics were worth $132,366,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Capital International Investors raised its stake in shares of CRISPR Therapeutics by 1.0% in the third quarter. Capital International Investors now owns 5,649,258 shares of the company’s stock valued at $366,128,000 after acquiring an additional 55,511 shares in the last quarter. State Street Corp raised its stake in shares of CRISPR Therapeutics by 35.6% in the second quarter. State Street Corp now owns 3,270,596 shares of the company’s stock valued at $159,082,000 after acquiring an additional 859,334 shares in the last quarter. Orbis Allan Gray Ltd raised its stake in shares of CRISPR Therapeutics by 76.9% in the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock valued at $134,467,000 after acquiring an additional 1,201,600 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of CRISPR Therapeutics by 2.9% in the third quarter. Vanguard Group Inc. now owns 2,364,645 shares of the company’s stock valued at $153,253,000 after acquiring an additional 66,556 shares in the last quarter. Finally, SR One Capital Management LP raised its stake in shares of CRISPR Therapeutics by 94.4% in the third quarter. SR One Capital Management LP now owns 2,038,763 shares of the company’s stock valued at $132,132,000 after acquiring an additional 989,812 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Needham & Company LLC increased their price objective on CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, February 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Monday, April 20th. Bank of America reduced their price objective on CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a research note on Thursday, January 22nd. Citizens Jmp reduced their price objective on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a research note on Friday, January 30th. Finally, TD Cowen raised their price target on CRISPR Therapeutics from $40.00 to $45.00 and gave the company a “hold” rating in a research note on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $64.53.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 3,182 shares of the firm’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $46.78, for a total transaction of $148,853.96. Following the transaction, the general counsel owned 94,308 shares of the company’s stock, valued at approximately $4,411,728.24. This trade represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 10,020 shares of CRISPR Therapeutics stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $46.78, for a total value of $468,735.60. Following the sale, the chief executive officer owned 255,501 shares in the company, valued at $11,952,336.78. This trade represents a 3.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 51,828 shares of company stock worth $2,578,097 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock opened at $52.34 on Friday. CRISPR Therapeutics AG has a 1-year low of $33.03 and a 1-year high of $78.48. The stock has a market cap of $5.05 billion, a PE ratio of -8.03 and a beta of 1.80. The stock’s fifty day moving average is $52.43 and its two-hundred day moving average is $54.93.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Friday, February 13th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The business had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. During the same quarter in the prior year, the business earned ($1.01) earnings per share. The firm’s quarterly revenue was down 97.8% on a year-over-year basis. On average, research analysts expect that CRISPR Therapeutics AG will post -4.93 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.